补体因子I罕见变异p.Ile357Met在溶血性尿毒症综合征中的热点
该研究回顾性分析法国HUS注册库2007-2022年数据,发现10例无关患者携带CFI罕见变异p.Ile357Met。其中7例原肾aHUS,5例合并恶性高血压,5例进展至肾衰竭需替代治疗;4例肾移植后3例发生C3肾小球病但无aHUS复发;另3例肾移植后发生新发TMA。提示该变异是HUS的易感遗传因素。
要点
- CFI p.Ile357Met变异携带者aHUS常合并恶性高血压,肾预后差。
- 肾移植后需警惕C3肾小球病或新发TMA,但aHUS复发少见。
- 该变异外显率低,可能为HUS的易感因素而非唯一病因。
核心结论
- CFI罕见变异p.Ile357Met可能是HUS及部分继发性HUS的易感遗传因素。
研究设计与样本
- 回顾性研究,从法国HUS注册库2007年1月至2022年1月纳入患者中识别携带孤立p.Ile357Met CFI错义变异的患者。
- 共纳入10例无关患者,70%为女性,HUS诊断中位年龄36.5岁。
主要发现
- 7例(病例1-7)原肾aHUS,其中5例合并恶性高血压,均未接受C5抑制剂治疗。
- 2例发生于围产期且肾功能完全恢复,5例进展至肾衰竭需替代治疗(KFRT)。
- 4例KFRT后接受肾移植,其中3例移植肾发生C3肾小球病,但无aHUS复发。
- 3例(病例8-10)肾移植后发生新发血栓性微血管病,由不同触发因素诱发。
临床怎么用
- 对aHUS患者应关注CFI p.Ile357Met变异筛查,尤其合并恶性高血压者。
- 携带该变异者肾移植后需监测C3肾小球病和新发TMA,但aHUS复发风险可能较低。
局限性
- 回顾性研究,样本量小(10例),来自单一国家注册库。
- 未评估该变异的功能影响及外显率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Atypical hemolytic uremic syndrome (aHUS) is a rare kidney disease due to a dysregulation of the complement alternative pathway. Complement factor I (CFI) negatively regulates the alternative pathway and CFI gene rare variants have been associated to aHUS with a low disease penetrance. We report 10 unrelated cases of HUS associated to a rare CFI variant, p.Ile357Met (c.1071T>G). All patients with isolated p.Ile357Met CFI missense variant were retrospectively identified among patients included between January 2007 and January 2022 in the French HUS Registry. We identified 10 unrelated patients (70% women; median age at HUS diagnosis, 36.5 years) who carry the same rare variant p.Ile357Met in the CFI gene. Seven patients (cases 1-7) presented with aHUS in the native kidney associated with malignant hypertension in 5 patients. None received a C5 inhibitor. Two of these cases occurred in the peripartum period with complete recovery of kidney function, while 5 of these patients reached kidney failure requiring replacement therapy (KFRT). Four patients with KFRT subsequently underwent kidney transplantation. Three later developed C3 glomerulopathy in their kidney graft, but none had aHUS recurrence. Three other patients (cases 8-10) experienced de novo thrombotic microangiopathy after kidney transplantation, precipitated by various triggers. The rare CFI variant p.Ile357Met appears to be a facilitating genetic factor for HUS and for some forms of secondary HUS.
引用
- Schwotzer N, Fakhouri F, Martins PV, et al. Hot Spot of Complement Factor I Rare Variant p.Ile357Met in Patients With Hemolytic Uremic Syndrome. Am J Kidney Dis. 2024. PMID: 38423159. doi:10.1053/j.ajkd.2023.12.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。